The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 3, 2002, Pages 181-186

  Antovic, Aleksandra ^a   Blomback M ^a   Bremme, K ^a   He, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dalteparin; Low molecular mass (weight) heparin; Method; Overall haemostasis potential; Pregnancy; Prophylaxis; Thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG MONITORING; FEMALE; GESTATIONAL AGE; HEMOSTASIS; HUMAN; PREGNANCY; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; DALTEPARIN; FACTOR XA; FEMALE; FIBRIN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK; THROMBIN; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0036526572     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200204000-00002     Document Type: Article

References (14)

1. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results
2. A simple and rapid laboratory method for determination of haemostasis potential in plasma - II modifications for use in routine laboratories and research work
3. A phamacokinetic study of dalteparin (Fragmin®) during late pregnancy
4. Mutation in blood coagulation factor V associated with resistance to activated protein C
5. Thromboprophylaxis with low molecular mass heparin, Fragmin (dalteparin), during pregnancy - A longitudinal safety study
6. Assay of heparin in plasma using a chromogenic substrate for activated factor X
7. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay
8. The risk of antenatal subcutaneus heparin prophylaxis: A controlled trial
9. Recurrence of venous thromboembolic disease and use of oral contraceptives
10. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and puerperium
11. Blood clotting activation during normal pregnancy
12. Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy
13. Monitoring of a women with protein C deficiency during pregnancy and the effects of heparin
14. The effect of prophylactic heparin treatment on enhanced thrombin generation in pregnancy